ScripAbbVie is expanding its presence in the emerging field of trispecific antibodies for multiple myeloma with a second licensing deal, this time with IGI Therapeutics for ISB 2001, a CD38xBCMAxCD3-direct
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. SunRock, Escugen Partner To Develo
ScripJiangsu Hengrui Pharmaceuticals, China’s top innovative drug maker by pipeline size, is set to spring back into the high-stakes arena of global Phase III clinical trials which include sites in the US
ScripThese are interesting times for Almirall and CEO Carlos Gallardo believes the Spanish firm holds “a unique position as the only company that focuses exclusively on medical dermatology and has capabili